ACTG A5217

Study Drugs
Step 1:
Arm A: tenofovir DF, emtricitabine and lopinavir/ritonavir for 36 weeks

Arm B: No treatment

Step 2:
Both Arms A and B: tenofovir DF, emtricitabine and lopinavir/ritonavir

Eligibility Criteria

CD4 > 350